全文获取类型
收费全文 | 29472篇 |
免费 | 6811篇 |
国内免费 | 784篇 |
专业分类
耳鼻咽喉 | 705篇 |
儿科学 | 686篇 |
妇产科学 | 766篇 |
基础医学 | 1145篇 |
口腔科学 | 2787篇 |
临床医学 | 5276篇 |
内科学 | 6325篇 |
皮肤病学 | 502篇 |
神经病学 | 2220篇 |
特种医学 | 1275篇 |
外国民族医学 | 7篇 |
外科学 | 4653篇 |
综合类 | 1748篇 |
现状与发展 | 16篇 |
一般理论 | 1篇 |
预防医学 | 3409篇 |
眼科学 | 467篇 |
药学 | 1142篇 |
9篇 | |
中国医学 | 591篇 |
肿瘤学 | 3337篇 |
出版年
2024年 | 210篇 |
2023年 | 1242篇 |
2022年 | 722篇 |
2021年 | 1112篇 |
2020年 | 1569篇 |
2019年 | 768篇 |
2018年 | 1629篇 |
2017年 | 1547篇 |
2016年 | 1744篇 |
2015年 | 1924篇 |
2014年 | 2449篇 |
2013年 | 2804篇 |
2012年 | 1372篇 |
2011年 | 1376篇 |
2010年 | 1813篇 |
2009年 | 2282篇 |
2008年 | 1156篇 |
2007年 | 933篇 |
2006年 | 1073篇 |
2005年 | 897篇 |
2004年 | 653篇 |
2003年 | 643篇 |
2002年 | 512篇 |
2001年 | 621篇 |
2000年 | 486篇 |
1999年 | 588篇 |
1998年 | 633篇 |
1997年 | 618篇 |
1996年 | 623篇 |
1995年 | 480篇 |
1994年 | 372篇 |
1993年 | 301篇 |
1992年 | 220篇 |
1991年 | 188篇 |
1990年 | 182篇 |
1989年 | 165篇 |
1988年 | 140篇 |
1987年 | 143篇 |
1986年 | 127篇 |
1985年 | 106篇 |
1984年 | 79篇 |
1983年 | 96篇 |
1982年 | 84篇 |
1981年 | 71篇 |
1980年 | 47篇 |
1979年 | 33篇 |
1978年 | 32篇 |
1977年 | 43篇 |
1976年 | 31篇 |
1975年 | 27篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
3.
Maaike van Gerwen MD Naomi Alpert MS Raja Flores MD Emanuela Taioli MD PhD 《American journal of industrial medicine》2020,63(2):115-120
The association between asbestos exposure, mainly in occupational settings, and malignant mesothelioma has been well established; this has prompted several countries to establish mesothelioma epidemiologic surveillance programs often at the request of national agencies. This review compares currently existing mesothelioma registries worldwide to develop a concept model for a US real-time case capture mesothelioma registry. Five countries were identified with a mesothelioma specific registry, including Italy, France, UK, Australia, and South Korea. All, except the UK, used interviews to collect exposure data. Linkage with the national death index was available or was in future plans for all registries. The registries have limited information on treatment, quality of life, and other patient-centered outcomes such as symptoms and pain management. To thoroughly collect exposure data, “real-time” enrollment is preferable; to maximize the capture of mesothelioma cases, optimal coverage, and a simplified consent process are needed. 相似文献
4.
Chie Teramoto PHN RN MS Satoko Nagata PhD PHN RN Reiko Okamoto PhD PHN RN Ruriko Suzuki PHN RN MS Emiko Kishi PhD PHN RN Michie Nomura DSN PHN RN Noriko Jojima PHN RN MS Masumi Nishida PhD PHN RN Keiko Koide PhD PHN RN Emiko Kusano PhD PHN RN Saori Iwamoto PhD PHN RN Sachiyo Murashima PhD PHN RN 《Public health nursing (Boston, Mass.)》2015,32(6):654-661
5.
人类微生物群是由寄生在人体上皮屏障的细菌和其他微生物组成的,其中大部分位于肠道内,与宿主之间形成共生的关系。机体肠道微生物的组成虽然受到年龄、饮食、生活方式等因素的影响,但在正常生理情况下是相对稳定的。近年来,肠道菌群与恶性肿瘤的关系越来越受到重视。肠道菌群不但能够维持局部稳态,还能调节机体代谢、炎症和免疫等生理过程。有研究表明,微生物群,特别是肠道菌群能够显著调节机体对癌症治疗的反应性以及机体对毒副反应的敏感性。检查肠道菌群中各菌种之间的比例可作为筛查恶性肿瘤的新方法。本文将综述微生物群具有影响肿瘤的发生发展、抗肿瘤治疗疗效以及药物不良反应的证据,以及其中所涉及的微生物种类,从而为恶性肿瘤精准治疗提供证据。 相似文献
6.
Katie Mycock Lin Zhan Gavin Taylor-Stokes Gary Milligan Debanjali Mitra 《Current oncology (Toronto, Ont.)》2021,28(1):678
Background: Palbociclib is a selective cyclin-dependent kinase (CDK) 4/6 inhibitor used in combination with aromatase inhibitors or fulvestrant for patients with hormone receptor-positive (HR+) human epidermal growth factor receptor 2 (HER2)-negative advanced/metastatic breast cancer (ABC/MBC). Palbociclib was the first CDK 4/6 inhibitor approved for HR+/HER2− ABC/MBC treatment in Canada in combination with letrozole (P+L) as an initial endocrine-based therapy (approved March 2016), or with fulvestrant (P+F) following disease progression after prior endocrine therapy (approved May 2017). The Ibrance Real World Insights (IRIS) study () collected real-world outcomes data for palbociclib-treated patients in several countries, including Canada. Methods: This retrospective chart review included women with HR+/HER2− ABC/MBC receiving P+L or P+F in Canada. Physicians reviewed medical records for up to 14 patients, abstracting demographic and clinical characteristics, treatment patterns, and clinical outcomes. Progression-free rates (PFRs) and survival rates (SRs) at 6, 12, 18, and 24 months were estimated via Kaplan–Meier analysis. Results: Thirty-three physicians examined medical records for 247 patients (P+L, n = 214; P+F, n = 33). Median follow-up was 8.8 months for P+L and 7.0 months for P+F. Most patients were initiated on palbociclib 125 mg/d (P+L, 90.2%; P+F, 84.8%). Doses were reduced in 16.6% of P+L and 14.3% of P+F patients initiating palbociclib at 125 mg/d. The PFR for P+L was 90.3% at 12 months and 78.2% at 18 months; corresponding SRs were 95.6% and 93.0%. For P+F, 6-month PFR was 91.0%; 12-month SR was 100.0%. Conclusions: Dose reduction rates were low and PFR and SR were high in this Canadian real-world assessment of P+L and P+F treatments, suggesting that palbociclib combinations are well tolerated and effective. NCT03159195相似文献
7.
8.
9.
10.